Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvalent, Inc. filings document a clinical-stage oncology company developing small-molecule inhibitors for clinically proven kinase targets. Its Form 8-K reports disclose operating and financial results, pipeline and clinical-trial updates for zidesamtinib and neladalkib, FDA submission events, material-event disclosures, and royalty or revenue-share arrangements for its investigational product candidates.
Proxy materials cover annual meeting governance, executive compensation, equity awards, and shareholder voting matters. Other disclosures describe Nuvalent's Class A common stock, capital-structure matters, research and development spending, cash resources, and regulatory considerations associated with advancing ROS1-, ALK-, and HER2-directed cancer programs.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom exercised stock options for 11,430 shares of Class A common stock at an exercise price of $1.08 per share. On the same date, she sold 11,430 shares in open-market transactions at weighted average prices between $103.81 and $106.69.
The filing shows these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, indicating the sales were scheduled in advance. Following the transactions, Balcom directly holds 85,533 shares of Nuvalent Class A common stock.
Nuvalent, Inc. reported that officer Benjamin Lane received new equity-based compensation. On April 1, 2026, Lane was granted a stock option for 19,000 shares of Class A common stock at an exercise price of $105.64 per share, expiring in 2036. He also received 9,500 shares of Class A common stock in the form of restricted stock units, which vest in three equal annual installments starting after April 1, 2026, subject to continued service. Following the RSU grant, Lane directly holds 50,368 shares of Class A common stock.
Nuvalent, Inc. Chief Development Officer Darlene Noci exercised stock options and sold shares in a planned transaction. She exercised options to acquire 5,500 shares of Class A Common Stock at $27.85 per share, then sold 5,500 shares in two open-market trades at weighted average prices of $97.43 and $98.13, all under a Rule 10b5-1 trading plan adopted on November 18, 2024. After these transactions, she directly holds 58,117 shares of Class A Common Stock and 97,829 option shares, indicating she retains a substantial equity stake despite the routine liquidity event.
NUVL notified the sale of 22,000 shares of Class A Common under Rule 144 related to a stock option exercise, to be effected on 03/30/2026 for cash. The filing also lists prior open-market disposals of 4,000, 5,500, and 5,500 shares on 12/30/2025, 01/29/2026, and 02/26/2026, respectively.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller exercised stock options and sold shares in a planned transaction. She exercised options to acquire 5,500 shares of Class A Common Stock at an exercise price of $6.89 per share, from options that are fully vested. On the same date, she sold a total of 5,500 shares in three open-market trades at weighted average prices around $97.50–$99.46 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024. After these transactions, she directly holds 59,634 shares of Class A Common Stock and retains 83,608 stock options outstanding, according to the filing.
The Vanguard Group filed an amendment to Schedule 13G reporting zero beneficial ownership of Nuvalent Inc. common stock. The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The Schedule 13G/A shows 0 shares and 0% ownership and is signed by Ashley Grim on 03/27/2026.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported an exercise-and-sale set of transactions in company stock. On March 24, 2026, she exercised stock options for 11,430 shares of Class A Common Stock at $1.08 per share and sold 11,430 shares that day in open-market trades at weighted-average prices in the mid-$90s. She then sold an additional 13,700 shares on March 25, 2026 at a weighted-average price of $100.16 per share in open-market transactions. All sales were executed under a Rule 10b5-1 trading plan adopted on December 23, 2025. After these transactions, she directly holds 85,533 shares of Nuvalent Class A Common Stock.
NUVL filed a Form 144 notice reporting proposed sales of Class A Common shares. The notice lists multiple lots and dates with specific quantities, including 30,019, 15,701, 4,728 and 8,972 shares tied to option exercises and cash transactions.
The filing identifies transactions dated 03/24/2026 and 12/17/2024 and names J.P. Morgan Securities LLC as an intermediary. The submission is a resale notice of insider-held securities under Form 144.
Nuvalent, Inc. officer Benjamin Lane filed an initial ownership report, listing his equity stake in the company. He directly holds 40,868 shares of Class A Common Stock, along with multiple stock options and restricted stock units that may convert into additional shares over time.
The filing shows stock options over 731, 8,333, 17,848, 15,052, 12,025 and 8,000 shares of Class A Common Stock, with exercise prices from $14.40 to $106.82 and expirations between 2032 and 2036. Footnotes also describe RSUs covering 6,733, 5,200 and 8,000 shares that vest in installments, subject to continued service. The Form 3 reflects holdings rather than new buy or sell transactions.
Nuvalent, Inc.’s Chief Scientific Officer Henry E. Pelish exercised stock options and sold shares of Class A Common Stock in mid-March 2026. He exercised options covering 17,320 shares at strike prices between $18.93 and $72.35, converting them into common shares.
On March 12–13, 2026, he then executed open-market sales totaling 35,104 shares at weighted average prices around the high‑$90s, in multiple trades across price ranges from $97.08 to $100.14. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. After these transactions, Pelish directly holds 65,604 shares of Nuvalent Class A Common Stock.